CO2021007916A2 - Ácido ribonucleico (arn) que codifica para una proteína - Google Patents
Ácido ribonucleico (arn) que codifica para una proteínaInfo
- Publication number
- CO2021007916A2 CO2021007916A2 CONC2021/0007916A CO2021007916A CO2021007916A2 CO 2021007916 A2 CO2021007916 A2 CO 2021007916A2 CO 2021007916 A CO2021007916 A CO 2021007916A CO 2021007916 A2 CO2021007916 A2 CO 2021007916A2
- Authority
- CO
- Colombia
- Prior art keywords
- protein
- rna
- codes
- ribonucleic acid
- mrna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un ARNm que comprende una secuencia de ácido nucleico que codifica para una proteína y un péptido de señal y una unidad de transcripción, un vector de expresión o un vector de terapia génica que comprende un ácido nucleico que codifica para una proteína y un péptido de señal; se describe también en la presente una composición terapéutica que comprende dicho ARNm, unidad de transcripción, vector de expresión o vector de terapia génica y el uso de la composición terapéutica en el tratamiento de una enfermedad o una condición.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18214221 | 2018-12-19 | ||
| EP19208066 | 2019-11-08 | ||
| PCT/EP2019/086019 WO2020127532A2 (en) | 2018-12-19 | 2019-12-18 | Rna encoding a protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021007916A2 true CO2021007916A2 (es) | 2021-09-20 |
Family
ID=68848313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0007916A CO2021007916A2 (es) | 2018-12-19 | 2021-06-16 | Ácido ribonucleico (arn) que codifica para una proteína |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220002364A1 (es) |
| EP (1) | EP3898982A2 (es) |
| JP (1) | JP2022514863A (es) |
| KR (1) | KR20210105382A (es) |
| CN (1) | CN113454227A (es) |
| AU (1) | AU2019407921A1 (es) |
| BR (1) | BR112021011771A2 (es) |
| CA (1) | CA3120638A1 (es) |
| CL (1) | CL2021001571A1 (es) |
| CO (1) | CO2021007916A2 (es) |
| IL (1) | IL284035A (es) |
| MA (1) | MA54503A (es) |
| MX (1) | MX2021007241A (es) |
| PE (1) | PE20211342A1 (es) |
| PH (1) | PH12021551135A1 (es) |
| SG (1) | SG11202105267VA (es) |
| TW (1) | TW202043477A (es) |
| WO (1) | WO2020127532A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021400488A1 (en) | 2020-12-14 | 2023-06-22 | Regeneron Pharmaceuticals, Inc. | Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors |
| JP2024504414A (ja) * | 2021-01-26 | 2024-01-31 | シギロン セラピューティクス， インコーポレイテッド | 抗原特異的免疫寛容を誘導するための組成物、デバイス及び方法 |
| WO2022187277A1 (en) * | 2021-03-01 | 2022-09-09 | The Johns Hopkins University | Molecular indexing of proteins by self assembly (mipsa) for efficient proteomic investigations |
| WO2022216944A1 (en) * | 2021-04-07 | 2022-10-13 | Mayo Foundation For Medical Education And Research | Methods and materials for reversing atherogenic plaque instability |
| JP2024515184A (ja) * | 2021-04-19 | 2024-04-05 | ヴェルサメブ アーゲー | 下部尿路症状の治療方法 |
| CN117813380A (zh) * | 2021-06-23 | 2024-04-02 | 维萨梅布有限公司 | 用于调节诸基因表达的组合物和方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1604688B1 (de) | 2001-06-05 | 2010-02-03 | CureVac GmbH | Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US20090047259A1 (en) * | 2005-12-22 | 2009-02-19 | Enrique Lara | Methods of Using the Calcineurin A Variant CnA-beta 1 |
| US9567382B2 (en) * | 2008-04-15 | 2017-02-14 | Genzyme Corporation | Methods to produce rod-derived cone viability factor (RdCVF) |
| EP2643468B1 (en) * | 2010-11-22 | 2018-07-04 | Amicus Therapeutics, Inc. | Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins |
| DK2797613T3 (da) * | 2011-10-27 | 2020-03-02 | Wellstat Ophthalmics Corp | Vektorer, der koder for rod-derived cone viability-faktor |
| WO2014005219A1 (en) * | 2012-07-02 | 2014-01-09 | Iprogen Biotech Inc. | Intracellular protein delivery |
| US10435694B2 (en) * | 2014-03-14 | 2019-10-08 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| WO2015162930A1 (ja) * | 2014-04-24 | 2015-10-29 | 一般社団法人 医療産業イノベーション機構 | タンパク質発現を向上させる方法およびタンパク質発現用組成物 |
| GB201705484D0 (en) * | 2017-04-05 | 2017-05-17 | Quethera Ltd | Genetic construct |
-
2019
- 2019-12-18 EP EP19818197.6A patent/EP3898982A2/en active Pending
- 2019-12-18 KR KR1020217021821A patent/KR20210105382A/ko active Search and Examination
- 2019-12-18 PE PE2021000874A patent/PE20211342A1/es unknown
- 2019-12-18 BR BR112021011771-7A patent/BR112021011771A2/pt unknown
- 2019-12-18 WO PCT/EP2019/086019 patent/WO2020127532A2/en active Application Filing
- 2019-12-18 SG SG11202105267VA patent/SG11202105267VA/en unknown
- 2019-12-18 CA CA3120638A patent/CA3120638A1/en active Pending
- 2019-12-18 JP JP2021535281A patent/JP2022514863A/ja active Pending
- 2019-12-18 MX MX2021007241A patent/MX2021007241A/es unknown
- 2019-12-18 MA MA054503A patent/MA54503A/fr unknown
- 2019-12-18 CN CN201980092197.7A patent/CN113454227A/zh active Pending
- 2019-12-18 AU AU2019407921A patent/AU2019407921A1/en active Pending
- 2019-12-19 TW TW108146645A patent/TW202043477A/zh unknown
-
2021
- 2021-05-19 PH PH12021551135A patent/PH12021551135A1/en unknown
- 2021-06-15 CL CL2021001571A patent/CL2021001571A1/es unknown
- 2021-06-15 IL IL284035A patent/IL284035A/en unknown
- 2021-06-16 US US17/348,876 patent/US20220002364A1/en active Pending
- 2021-06-16 CO CONC2021/0007916A patent/CO2021007916A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021011771A2 (pt) | 2021-08-31 |
| JP2022514863A (ja) | 2022-02-16 |
| AU2019407921A1 (en) | 2021-06-10 |
| PH12021551135A1 (en) | 2022-02-28 |
| CN113454227A (zh) | 2021-09-28 |
| MA54503A (fr) | 2021-10-27 |
| CA3120638A1 (en) | 2020-06-25 |
| WO2020127532A3 (en) | 2020-09-17 |
| KR20210105382A (ko) | 2021-08-26 |
| CL2021001571A1 (es) | 2022-04-18 |
| SG11202105267VA (en) | 2021-07-29 |
| TW202043477A (zh) | 2020-12-01 |
| MX2021007241A (es) | 2021-09-23 |
| IL284035A (en) | 2021-08-31 |
| PE20211342A1 (es) | 2021-07-26 |
| US20220002364A1 (en) | 2022-01-06 |
| WO2020127532A2 (en) | 2020-06-25 |
| EP3898982A2 (en) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021007916A2 (es) | Ácido ribonucleico (arn) que codifica para una proteína | |
| MX2021015753A (es) | Constructo de arn. | |
| BR112018013930A2 (pt) | vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus | |
| BR122021025194A8 (pt) | Molécula de ácido nucleico, método para obter rna, rna, método para obter um peptídeo ou proteína e usos in vitro ou ex vivo do rna | |
| CO2018012482A2 (es) | Formulaciones de un inhibidor de lsd1 | |
| WO2017191274A3 (en) | Rna encoding a therapeutic protein | |
| DOP2018000245A (es) | Proteinas de fusion gdf15 y usos de estas | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| CO2018004564A2 (es) | Genes de ataxia de friedreich modificados y vectores para terapia génica | |
| CO2021002965A2 (es) | Moléculas de ácido nucleico y sus usos para la terapia génica no viral | |
| PE20181206A1 (es) | Construcciones especificas del higado, casetes de expresion del factor viii y metodos de uso de estos | |
| CL2019003405A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| CY1124667T1 (el) | Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα | |
| PE20230430A1 (es) | Composiciones y metodos para modular simultaneamente la expresion de genes | |
| MX2021006253A (es) | Terapias génicas para enfermedad neurodegenerativa. | |
| UY39464A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| AR114540A1 (es) | VARIANTE DE ARNi CONTRA a-SINUCLEÍNA | |
| EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака | |
| CL2017003201A1 (es) | Variantes de il-37 | |
| CL2020001494A1 (es) | Uso de una proteína no estructural de prv para proteger contra la inflamación del músculo esquelético y cardíaco. | |
| DK1587828T3 (da) | Defensivproteiner | |
| MX2019014697A (es) | Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. | |
| EA202191148A1 (ru) | Рнк, кодирующая белок | |
| AR121961A1 (es) | Inmunoterapia con citocina | |
| AR099641A1 (es) | OSTEONECTINA (SPARC) COMO BLANCO TERAPÉUTICO PARA EL TRATAMIENTO Y PREVENCIÓN DEL FALLO HEPÁTICO AGUDO, COMPOSICIÓN FARMACEUTICA, CONSTRUCTO GENÉTICO, ARNsi, AGENTE QUE INHIBE LA EXPRESIÓN, USO |